560 related articles for article (PubMed ID: 19846394)
21. [Pre-occupying increase in diabetes as cause for terminal kidney failure. Evaluation of treatment strategies].
Pérez García R; Rodríguez Benítez P; Dall'Anesse C; Gómez Campderá F; Valderrábano F
An Med Interna; 2001 Apr; 18(4):175-80. PubMed ID: 11496535
[TBL] [Abstract][Full Text] [Related]
22. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
23. Patients with end stage renal disease: a registry at Sultanah Aminah Hospital, Johor Bahru, Malaysia.
Liu WJ; Hooi LS
Med J Malaysia; 2007 Aug; 62(3):197-200. PubMed ID: 18246906
[TBL] [Abstract][Full Text] [Related]
24. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and survival of young adults who started renal replacement therapy during childhood.
Kramer A; Stel VS; Tizard J; Verrina E; Rönnholm K; Pálsson R; Maxwell H; Jager KJ
Nephrol Dial Transplant; 2009 Mar; 24(3):926-33. PubMed ID: 18840894
[TBL] [Abstract][Full Text] [Related]
26. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
27. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee.
Brunner FP; Selwood NH
Nephrol Dial Transplant; 1994; 9(10):1371-6. PubMed ID: 7816247
[TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
29. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
30. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease.
Conway B; Webster A; Ramsay G; Morgan N; Neary J; Whitworth C; Harty J
Nephrol Dial Transplant; 2009 Jun; 24(6):1930-7. PubMed ID: 19181760
[TBL] [Abstract][Full Text] [Related]
31. The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration.
Hommel K; Rasmussen S; Madsen M; Kamper AL
Nephrol Dial Transplant; 2010 Mar; 25(3):947-51. PubMed ID: 19861312
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
[TBL] [Abstract][Full Text] [Related]
33. Kidney transplant outcomes in patients with Fabry disease.
Shah T; Gill J; Malhotra N; Takemoto SK; Bunnapradist S
Transplantation; 2009 Jan; 87(2):280-5. PubMed ID: 19155985
[TBL] [Abstract][Full Text] [Related]
34. Trends in renal replacement therapy in Turkey, 1996-2008.
Süleymanlar G; Serdengeçti K; Altiparmak MR; Jager K; Seyahi N; Erek E;
Am J Kidney Dis; 2011 Mar; 57(3):456-65. PubMed ID: 21335249
[TBL] [Abstract][Full Text] [Related]
35. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
36. Increases in renal replacement therapy in Australia and New Zealand: understanding trends in diabetic nephropathy.
Grace BS; Clayton P; McDonald SP
Nephrology (Carlton); 2012 Jan; 17(1):76-84. PubMed ID: 21854505
[TBL] [Abstract][Full Text] [Related]
37. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
38. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
39. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
40. [Two cases of heterozygous Fabry disease].
Shibuya Y; Oku N; Suzuki Y; Gomi T
Nihon Jinzo Gakkai Shi; 2006; 48(5):421-7. PubMed ID: 16913464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
